Colon Cancer Alliance - high out-of-pocket costs
The Colon Cancer Alliance is committed to providing support and empowerment to those who are affected by colon cancer. This is why we’re actively addressing the patient impact of high out-of-pocket costs for medicine. Due to increased costs, patients are making decisions about treatment based on financial implication as opposed to selecting the best treatment path to address their current condition. The Affordable Care Act and Health Insurance Exchanges were intended to address the need for affordable care. The new Avelere study supports the patient stories we often hear. High copays and deductibles can create a fina...
Source: PHRMA - June 13, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
Again, Oxaliplatin Is Toxic and No Benefit in Rectal CancerAgain, Oxaliplatin Is Toxic and No Benefit in Rectal Cancer
Yet another rectal cancer study has found that the addition of oxaliplatin to capecitabine chemoradiation in locally advanced disease gives no short-term postoperative benefit and increases toxicity. Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 7, 2014 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Resected Pancreatic Cancer: Why Wait for the Inevitable?Resected Pancreatic Cancer: Why Wait for the Inevitable?
Dr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy. Medscape Oncology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 4, 2014 Category: Gastroenterology Tags: Hematology-Oncology Commentary Source Type: news
Oncothyreon and Array start phase 1b ONT-380 combination trial to treat metastatic HER2+ breast cancer
US-based Oncothyreon and Array BioPharma have started a phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda (capecitabine) and/or Herceptin (trastuzumab) for the treatment of patients with metastatic HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 4, 2014 Category: Pharmaceuticals Source Type: news
A New, Simpler Standard of Treatment in Rectal CancerA New, Simpler Standard of Treatment in Rectal Cancer
Capecitabine is a pill and, in an NCI-sponsored study, it provided the same outcomes as chemotherapy that requires infusion. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 21, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New Regimen for Elderly Patients With mCRCNew Regimen for Elderly Patients With mCRC
Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer. Medscape Oncology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 17, 2014 Category: Gastroenterology Tags: Hematology-Oncology Commentary Source Type: news
Capecitabine Linked to Potentially Fatal Skin ReactionsCapecitabine Linked to Potentially Fatal Skin Reactions
According to the manufacturer, capecitabine has been linked to severe and potentially fatal skin reactions. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Capecitabine Accord launch in Europe
Accord is launching the generic version of Xeloda®, Capecitabine Accord film - coated tablets. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 3, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Oncology Latest News Source Type: news
Bevacizumab Plus Capecitabine Benefits in Elderly mCRCBevacizumab Plus Capecitabine Benefits in Elderly mCRC
Elderly patients with metastatic colorectal cancer (mCRC) benefit from combining bevacizumab with capecitabine. Is this a new standard of care? Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA Approves Generic CapecitabineFDA Approves Generic Capecitabine
The first generic version of the oral chemotherapy agent capecitabine has been approved for the treatment of metastatic colorectal and breast cancer. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
US FDA approves generic version of Roche's cancer drug Xeloda
The US Food and Drug Administration (FDA) has approved a generic version of Roche Holding's oral chemotherapy pill, Xeloda (capecitabine). (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2013 Category: Pharmaceuticals Source Type: news
FDA approves first generic of Xeloda for colon cancer
The US Food and Drug Administration has given approval to Teva Pharmaceuticals for the first generic version of Roche's colon cancer drug Xeloda. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 17, 2013 Category: Pharmaceuticals Source Type: news
First Generic Version of Xeloda Approved
Title: First Generic Version of Xeloda ApprovedCategory: Health NewsCreated: 9/16/2013 4:35:00 PMLast Editorial Review: 9/17/2013 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 17, 2013 Category: Cancer & Oncology Source Type: news
Generic Capecitabine Approved for Advanced Colorectal and Breast Cancers (FREE)
By Kristin J. Kelley
The FDA has approved the first generic version of the oral chemotherapy drug capecitabine (Xeloda) … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 17, 2013 Category: Primary Care Source Type: news
FDA OKs Generic Xeloda
WASHINGTON (MedPage Today) -- The FDA has approved a generic version of the oral metastatic colorectal cancer drug capecitabine (Xeloda). (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 16, 2013 Category: Primary Care Source Type: news
